Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab With or Without Sunitinib in Sunitinib-Refractory mRCC
NCT00556205Phase 2Withdrawn
- Sponsor
- Massachusetts General Hospital
- Start
- Sep 2009
- Primary completion
- Sep 2009
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 2 trial of bevacizumab in renal cell carcinoma (RCC), sponsored by Massachusetts General Hospital. Planned start Sep 2009; status: withdrawn.
02
Drugs
bevacizumab
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT00556205.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00556205.